- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05423665
Speckle Tracking Ecocardiography como uma ferramenta para o diagnóstico precoce de crescimento fetal prejudicado em gestações gemelares (HEART)
In this project there are 2 time points during the pregnancy included, namely at 21 weeks and 30 weeks of gestation, to measure the predictive values of FGR, strain and strain rate. The fetal growth parameters will be collected at the same time points, to define the growth (differences) throughout gestation of both fetuses. A maternal blood sample will be taken at 21 weeks of gestation to identify the level of exposure to air pollution (black carbon) and the level of biochemical markers of placental dysfunction. Doppler ultrasounds will be used for antenatal identification of placenta insufficiency. At birth, umbilical cord blood and the placenta will be collected. The placenta will be examined, to identify morphological findings which are associated with FGR. The umbilical cord blood and placental biopsy will be used for the level of exposure to air pollution and the level of oxidative stress. One to three days after birth, neonatal strain and strain rate will be measured to define postnatal cardiac remodeling as well as the neonatal blood pressure as cardiovascular risk factor.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Fetal growth restriction (FGR) is diagnosed in 5-10% of the pregnancies. After preterm birth, it is the second leading cause of perinatal morbidity and mortality. Twin pregnancies have a higher occurrence of FGR than singletons, in monochorionic (MC) twin pregnancies it's diagnosed in 19.7% of the cases and in dichorionic (DC) twin pregnancies in 10.5% of the cases. Fetuses with FGR are at greater risk of perinatal morbidity and mortality and even long-term health defects. From a public health perspective, it's important to correctly diagnose FGR to adjust the antenatal and postnatal care and to have more insight into the factors influencing early onset cardiovascular disease. STE has a strong predictive value for cardiovascular function, therefore it would be a promising tool to add in the routine pregnancy clinical care. Speckle tracking echocardiography (STE) is a relative new technique especially in the pregnancy follow up, which permits offline calculation of myocardial velocities and deformation parameters. These parameters, including strain and strain rate, provide information about the fetal myocardial function. Apart from investigating if STE can be used for the prediction of FGR, we will also investigate the association between fetal exposure to air pollution and in utero cardiac remodeling. Indeed, it is known that inhalation of particulate matter (e.g. black carbon) during the pregnancy can reach the placenta and lead to alterations in the placenta's function including increases in oxidative stress markers. Early life exposure to black carbon has been associated with adverse cardiovascular health outcomes and reduction of fetal growth, especially in multiple gestation pregnancies.
In this project we will include 2 time points during the pregnancy, namely at 21 weeks and 30 weeks of gestation, to measure the predictive values of FGR, strain and strain rate. The fetal growth parameters will be collected at the same time points, to define the growth (differences) throughout gestation of both fetuses. A maternal blood sample will be taken at 20 weeks of gestation to identify the level of exposure to air pollution (black carbon) and the level of biochemical markers of placental dysfunction. Doppler ultrasounds will be used for antenatal identification of placenta insufficiency. At birth, umbilical cord blood and the placenta will be collected. The placenta will be examined, to identify morphological findings which are associated with FGR. The umbilical cord blood and placental biopsy will be used for the level of exposure to air pollution and the level of oxidative stress. One to three days after birth, neonatal strain and strain rate will be measured to define postnatal cardiac remodeling as well as the neonatal blood pressure as cardiovascular risk factor.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Eline Meireson
- Número de telefone: 0032 9 332 78 17
- E-mail: eline.meireson@uzgent.be
Locais de estudo
-
-
-
Ghent, Bélgica, 9000
- Recrutamento
- Ghent University Hospital
-
Contato:
- Kristien Roelens, prof. dr.
-
Leuven, Bélgica, 3000
- Ainda não está recrutando
- Universitair ziekenhuis Leuven
-
Contato:
- Liebeth Lewie, prof. dr.
-
-
-
-
-
Eindhoven, Holanda, 5631
- Ainda não está recrutando
- Maxima medical center
-
Contato:
- Judith van Laar, dr.
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
The number of subjects that will be included in this study is: 600 neonates (200 twin pairs and 200 singletons) and 400 pregnant mothers.
The fetuses are divided into following sub-groups:
- Appropriately grown
- Fetal growth restricted
- Selective fetal growth restricted (specific for twins)
Descrição
Inclusion Criteria:
- Singleton or dichorionic twin pregnancy
- Pregnant women 21 weeks ( ± 2 weeks) of gestation at the first visit
- Women ≥ 18 years
Exclusion Criteria:
- Women pregnant of multiples of higher order (≥3 siblings) Monochorionic twin pregnancy
- Fetal arrhythmia
- Known fetal congenital or genetic abnormalities
- Any suspicion of congenital fetal anomalies that might influence fetal cardiac function
- Pre-existing maternal hypertensive disease
- Autoimmune disease including systemic lupus erythematosus
- History of stillbirth
- Diabetes mellitus (mother)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: CASE_CONTROL
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Fetal growth restricted
Observation of cardiac remodeling perinatal and postnatal |
blood sample at 21 weeks of gestation clips of the fetal heart at 21 weeks of gestation, 30 weeks of gestation and 1-3 days after birth collection of umbilical cord blood at birth collection of the placenta at birth |
|
Appropriately grown
Observation of cardiac remodeling perinatal and postnatal |
blood sample at 21 weeks of gestation clips of the fetal heart at 21 weeks of gestation, 30 weeks of gestation and 1-3 days after birth collection of umbilical cord blood at birth collection of the placenta at birth |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
To assess the change in strain measured by speckle tracking echocardiography as a tool for early diagnosis of impaired fetal growth in multiple gestations
Prazo: Prenatal to 1-3 days after birth
|
to determine the change in fetal strain and strain rate in twin pregnancies in comparison with fetal growth |
Prenatal to 1-3 days after birth
|
|
To determine the intra-pair differences in fetal growth and strain (cardiac remodeling) in multiple gestations.
Prazo: Prenatal to 1-3 days after birth
|
to compare changes in strain and strain rate with fetal growth within 1 twin pair |
Prenatal to 1-3 days after birth
|
|
To compare the strain values (cardiac remodeling) between singletons and twin pregnancies
Prazo: Prenatal to 1-3 days after birth
|
to compare the changes in strain and strain rate between singletons and twin pregnancies |
Prenatal to 1-3 days after birth
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
To investigate the association between placenta functioning and in utero cardiac remodeling
Prazo: Prenatal to 1-3 days after birth
|
to evaluate placenta insufficiency (Doppler ultrasound, biochemical marker) with strain and strain rate |
Prenatal to 1-3 days after birth
|
|
To explore in utero cardiac remodeling in association with neonatal cardiovascular health
Prazo: Prenatal to 1-3 days after birth
|
to evaluate strain and strain rate with the neonatale blood pressure and heart rate |
Prenatal to 1-3 days after birth
|
|
To study the association between prenatal air pollution exposure and in utero cardiac remodeling
Prazo: Prenatal to 1-3 days after birth
|
to evaluate prenatal air pollution (black carbon particles in blood sample mother and placenta) with strain and strain rate |
Prenatal to 1-3 days after birth
|
|
To investigate placenta functioning as a mediator between air pollution and cardiac remodeling
Prazo: Prenatal to 1-3 days after birth
|
To evaluate prenatal air pollution (black carbon particles in blood sample mother and placenta) with placenta insufficiency (biochemical marker, Doppler ultrasound) |
Prenatal to 1-3 days after birth
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Kristien Roelens, University Hospital, Ghent
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Processos Patológicos
- Condições Patológicas, Anatômicas
- Doenças urogenitais femininas e complicações na gravidez
- Complicações na Gravidez
- Doenças Fetais
- Distúrbios do crescimento
- Doenças da Placenta
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Condições Patológicas, Sinais e Sintomas
- Retardo do crescimento fetal
- Remodelação Ventricular
- Insuficiência Placentária
- Técnicas de investigação
- Técnicas de laboratório clínico
- Técnicas e procedimentos de diagnóstico
- Diagnóstico
- Manipulação de amostras
Outros números de identificação do estudo
- ONZ-2022-0193
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .